Boots is reacquiring from Marion all U.S. rights to the tricyclic antidepressant (dothiepin HCl), which is not yet approved in the U.S. The agreement includes cash and other periodic payments based on Boots' sales. Boots markets the product in 14 countries; Marion, which obtained U.S. rights in the early 1970s, will continue all R&D under the existing NDA until FDA approval.
You may also be interested in...
Health technology assessment body NICE has now recommended that selective internal radiation therapy can be used on England’s National Health Service for treating advanced liver cancer.
A “structured dialog” led by the European Commission with pharmaceutical industry stakeholders provides a critical opportunity to address weaknesses in the stability and security of the supply chain by improving the environment for local manufacturing, Medicines for Europe believes.
Despite a slight increase in revenue, South Africa’s Adcock continues to struggle as it reports a continued drop in gross profit. The company expects the economy to remained constrained due to COVID-19, but is eagerly anticipating recovery with the government’s vaccine roll-out.